A Phase 3 Randomized Double-Blind Placebo- and Active-Comparator- Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma

Brief description of study

This study wants to find out if a new treatment called V940, when used with pembrolizumab, has fewer side effects and is more effective than just using pembrolizumab alone for people who had surgery for their risky skin cancers. Before starting the treatment, everyone must give some blood and a piece of their tumor for testing. Then, they'll be put into two groups: one getting the new treatment and the other getting a fake treatment. The study will see how long it takes for the cancer to come back, how far it spreads, and how long people live. They'll also keep an eye out for any severe side effects from the treatment. The study team plans to check the results at different times, and a team outside the study will look at the results and give advice on what to do next.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.